Sanofi unit acquires Rolaids from J&J

Don Riker…said: ‘This is probably a smart move on everybody’s part. It’s the kind of niche Chattem has a long history of acquiring and growing. For J&J it allows them to refocus on Tylenol and not be distracted by smaller niche brands"

click to read

J&J Sells Rolaids To Sanofi, But What Goes Next?

“Divesting some of these brands may make great sense as a way of recouping some value, avoiding further losses and reducing risk,” Donald Kay Riker, who runs OnPoint Advisors, a consumer healthcare products consulting firm, and editor of OTC Product News, writes us.

click to read

Chattem To Revive Rolaids Line Bought From J&J

"Don Riker, president of On Point Advisors...expects the claims war between [Tums & Rolaids] to be centered on their acid neutralization stories, speed of relief and the presence or absence of magnesium hydroxide, which has a laxative effect, some would say to counteract the constipating effect of calcium carbonate."

click to read

Bayer Aspirin is Feeling Plenty Healthy

"Consumers are running scared," says Donald Riker, a consultant on over-the-counter drugs and editor of OTC Product News. "There's been a shift in the trust in the products and the brands."

click to read